Evidence map›Paper›PMID 33719081›Full record

SynthesisClinical and experimental pharmacology & physiology2021

Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.

Timotius Ivan Hariyanto, Devina Adella Halim, Claudia Jodhinata, Theo Audi Yanto, Andree Kurniawan

Open access · bronzeAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Clinical and experimental pharmacology & physiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 12 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 12 syntheses or guidelines pooled it, 87 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Colchicine for the treatment of COVID-19.The Cochrane database of systematic reviews · 2021
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Timotius Ivan HariyantoFaculty of Medicine, Pelita Harapan University, Karawaci, Tangerang, Indonesia.
Devina Adella HalimFaculty of Medicine, Pelita Harapan University, Karawaci, Tangerang, Indonesia.
Claudia JodhinataFaculty of Medicine, Pelita Harapan University, Karawaci, Tangerang, Indonesia.
Theo Audi YantoDepartment of Internal Medicine, Faculty of Medicine, Pelita Harapan University, Karawaci, Tangerang, Indonesia.
Andree KurniawanDepartment of Internal Medicine, Faculty of Medicine, Pelita Harapan University, Karawaci, Tangerang, Indonesia.ORCID 0000-0002-5219-9029
Pelita Harapan University · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, there is no widely acceptable and proven effective treatment for coronavirus disease 2019 (COVID-19). Colchicine has been shown to offer a benefit in reducing the inflammation in several inflammatory diseases. This study aims to analyze the efficacy of colchicine administration and outcomes of COVID-19. We systematically searched the PubMed and Europe PMC database using specific keywords related to our aims until January 29, 2021. All articles published on COVID-19 and colchicine treatment were retrieved. The quality of the study was assessed using the Newcastle-Ottawa Scale (NOS) tool for observational studies and Revised Cochrane risk-of-bias tool for randomized trials (RoB 2) for clinical trial studies. Statistical analysis was done using Review Manager 5.4 software. A total of eight studies with 5778 COVID-19 patients were included in this meta-analysis. This meta-analysis showed that the administration of colchicine was associated with improvement of outcomes of COVID-19 [OR 0.43 (95% CI 0.34-0.55), p < 0.00001, I

Indexed as

COVID-19 Drug TreatmentColchicineCOVID-19HumansMortalityRandomized Controlled Trials as TopicSARS-CoV-2Treatment OutcomeTubulin ModulatorsColchicineTubulin Modulatorscolchicinecoronavirus disease 2019immune therapytreatment

Identifiers

PMID33719081
PMCPMC8250626
OpenAlexW3135947171

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.